Is Drotrecogin alfa (activated) for adults with severe sepsis, cost-effective in routine clinical practice?

INTRODUCTION: Previous cost-effectiveness analyses (CEA) reported that Drotrecogin alfa (DrotAA) is cost-effective based on a Phase III clinical trial (PROWESS). There is little evidence on whether DrotAA is cost-effective in routine clinical practice. We assessed whether DrotAA is cost-effective in...

Descripción completa

Detalles Bibliográficos
Autores principales: Sadique, M Zia, Grieve, Richard, Harrison, David A, Cuthbertson, Brian H, Rowan, Kathryn M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3334774/
https://www.ncbi.nlm.nih.gov/pubmed/21943177
http://dx.doi.org/10.1186/cc10468

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3334774/
https://www.ncbi.nlm.nih.gov/pubmed/21943177
http://dx.doi.org/10.1186/cc10468

Ejemplares similares